Natures Sunshine Products vs OPKO Health
NATR and OPK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How NATR and OPK compare
OPKO Health is the larger company, worth 6.7 times as much as Natures Sunshine Products ($1.2B against $182M).
Natures Sunshine Products grew revenue faster over the last twelve months (6.8% versus −11.5% for OPKO Health).
Natures Sunshine Products keeps more of each dollar of sales as profit, with a net margin of 3.7% compared with −12.4% at OPKO Health.
Natures Sunshine Products scores higher on the StockData Score (16 against 9 for OPKO Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | NATR | OPK |
|---|---|---|
| Size and price | ||
| Market cap | $182M | $1.2B |
| Share price | $10.33 | $1.62 |
| Change, 1 year | −51.2% | 26.6% |
| Change, 5 years | −39.5% | −60.8% |
| Beta (5Y) | 0.21 | 0.36 |
| Employees | 806 | 2,275 |
| StockData Score | ||
| Total score | 16 (better) | 9 |
| Valuation score | 6 (better) | 1 |
| Growth score | 2 (better) | 1 |
| Performance score | 2 | 3 (better) |
| Health score | 6 (better) | 4 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 10.2× | – |
| P/S | 0.4× (better) | 2.1× |
| P/B | – | 1.0× |
| EV/EBITDA | 2.3× (better) | 22.0× |
| P/FCF | 10.1× | – |
| FCF yield | 9.9% (better) | −11.1% |
| Fair value | $24.56 | $1.55 |
| Margin of safety | 57.9% (better) | −4.7% |
| Growth | ||
| Revenue growth (TTM) | 6.8% (better) | −11.5% |
| Revenue growth, 5Y average | 4.5% (better) | −15.8% |
| Net income growth (TTM) | 28.3% | – |
| EPS growth (TTM) | 36.5% | – |
| EPS growth, 5Y average | −0.19% | – |
| Profitability | ||
| Gross margin | 73.2% (better) | 40.8% |
| Operating margin | 6.0% (better) | −8.2% |
| Net margin | 3.7% (better) | −12.4% |
| FCF margin | 3.7% (better) | −22.8% |
| Return on equity | – | −5.9% |
| Return on invested capital | – | −4.0% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Net debt / EBITDA | – | −7.19 |
| Interest coverage | 208× | – |
| Current ratio | 2.60 | 3.35 (better) |
| Altman Z-score | 4.44 (better) | −0.21 |
| Piotroski F-score | 8 (better) | 4 |
| Dividends and buybacks | ||
| Buyback yield | 3.6% | 3.9% (better) |
| Shareholder yield | 3.6% | 3.9% (better) |
| Ownership | ||
| Held by institutions | 90.1% | 27.2% |
| Held by insiders | 25.5% | 43.6% |
| Insider net buying, 12 months | $3.7M (better) | −$13.2K |
| Short interest, % of float | 8.1% | 7.8% |
Go deeper
- NATR stock overview
- NATR income statement
- NATR valuation and score
- OPK stock overview
- OPK income statement
- OPK valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.